leisure time -WSS

leisure time

author：focus 2025-09-30 17:11:03 - browse：73384

A clipboard with checklist on blue dark background. -- health tech coverage from STAT — Adobe

A Pittsburgh artificial intelligence startup emerging as a challenger to Microsoft’s clinical note taking business has raised $150 million, a rare mega deal in a funding lull. The startup, Abridge, also has an unlikely cheerleader: Paul Ricci, the former head of Nuance, the service from Microsoft it competes with.

Abridge sells an AI tool that rapidly transcribes and summarizes doctors’ conversations with patients in a hospital’s electronic health records software. The startup’s leaders and investors tell STAT they’re betting that their medical knowledge, agility, and willingness to co-develop features with customers makes it a more attractive long term option than Nuance, which Microsoft says is currently used by most U.S. hospitals.

Microsoft, Abridge and other startups like Suki, Corti and Nabla are locked in a race to ease provider burnout by automating clinical note taking, and — thanks to generative AI — organizing the data in a way that could improve care, such as suggesting topics for follow-up, simplifying billing or analyzing trends at the broader patient population level.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Bird flu reported in person exposed to presumably infected cattle

WSS

First Opinion on colorectal cancer screening: letter and response

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Emergency medicine has repudiated 'excited delirium.' Now what?

U.K. decision on ALS drug has neurologists, advocates up in arms

Overprescribed: High cost isn't America's only drug problem

Scientists uncover potential path to treating deadly childhood tumor

focus

leisure time

hotspot

Medicare details structure of new drug price negotiation program

FDA has safety concerns on CRISPR

BioMarin wins approval for gene therapy to treat hemophilia A

Diversifying clinical trials isn't enough to close racial gaps: study

After affirmative action ruling, medical educators look to 'holistic review'

Pancreatic cancer is often deadly, but new discoveries are raising hope

In age of alternative facts, a scholarly course on calling out crap

Cassava reveals details — and problems — with Alzheimer's study

New air purifier tech could be key to improving indoor air quality

Pancreatic cancer is often deadly, but new discoveries are raising hope

knowledge

Readout Newsletter: XBI biotech index, Akero Therapeutics

Medicare Advantage 2025 payments will dip, Biden administration says

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

The pink breast cancer awareness ribbon needs a redesign

Chimpanzees, like humans and whales, get menopause: Study

hotspot

explore

entertainment

leisure time